Literature DB >> 8541880

Mutations in the human gene for fibrillin-1 (FBN1) in the Marfan syndrome and related disorders.

H C Dietz1, R E Pyeritz.   

Abstract

The extracellular microfibril, 10-14 nm in diameter, performs a number of functions, including serving as the scaffolding for deposition of tropoelastin to form elastic fibers. A variety of proteins compose the structure of microfibrils, the most prominent of which are the two fibrillins. Fibrillin-1 is encoded by FBN1 on human chromosome 15q21 and fibrillin-2 is encoded by FBN2 on 5q23. Each fibrillin monomer contains a large number of epidermal growth factor-like motifs, most capable of binding calcium ions, and a few motifs resembling the binding protein for transforming growth factor beta. In vitro polymerization of fibrillin monomers produces 'beads on a string' structures that look on electron microscopy much like microfibrils purified from the extracellular matrices of a variety of tissues. Mutations in FBN1 produce Marfan syndrome, a pleiotropic autosomal dominant connective tissue disorder with prominent manifestations in the skeleton, eye and cardiovascular system. A number of conditions related to Marfan syndrome are also due to FBN1 mutations. Contractural arachnodactyly is due to mutations in FBN2. In this paper we review the published mutations in these genes, preliminary results of genotype-phenotype correlations, and speculations regarding molecular pathogenesis.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 8541880     DOI: 10.1093/hmg/4.suppl_1.1799

Source DB:  PubMed          Journal:  Hum Mol Genet        ISSN: 0964-6906            Impact factor:   6.150


  110 in total

1.  Elastic-fiber pathologies: primary defects in assembly-and secondary disorders in transport and delivery.

Authors:  Z Urbán; C D Boyd
Journal:  Am J Hum Genet       Date:  2000-06-06       Impact factor: 11.025

2.  Fibrillin degradation by matrix metalloproteinases: implications for connective tissue remodelling.

Authors:  J L Ashworth; G Murphy; M J Rock; M J Sherratt; S D Shapiro; C A Shuttleworth; C M Kielty
Journal:  Biochem J       Date:  1999-05-15       Impact factor: 3.857

3.  A quantitative evaluation of SAGE.

Authors:  J Stollberg; J Urschitz; Z Urban; C D Boyd
Journal:  Genome Res       Date:  2000-08       Impact factor: 9.043

Review 4.  Management of Marfan syndrome.

Authors:  John C S Dean
Journal:  Heart       Date:  2002-07       Impact factor: 5.994

Review 5.  The pathogenesis of aortopathy in Marfan syndrome and related diseases.

Authors:  Jeffrey A Jones; John S Ikonomidis
Journal:  Curr Cardiol Rep       Date:  2010-03       Impact factor: 2.931

6.  The elastin fiber system between and adjacent to collector channels in the human juxtacanalicular tissue.

Authors:  Cheryl R Hann; Michael P Fautsch
Journal:  Invest Ophthalmol Vis Sci       Date:  2011-01-05       Impact factor: 4.799

7.  Abnormal mechanosensing and cofilin activation promote the progression of ascending aortic aneurysms in mice.

Authors:  Yoshito Yamashiro; Christina L Papke; Jungsil Kim; Lea-Jeanne Ringuette; Qing-Jun Zhang; Zhi-Ping Liu; Hamid Mirzaei; Jessica E Wagenseil; Elaine C Davis; Hiromi Yanagisawa
Journal:  Sci Signal       Date:  2015-10-20       Impact factor: 8.192

Review 8.  The molecular genetics of Marfan syndrome and related microfibrillopathies.

Authors:  P N Robinson; M Godfrey
Journal:  J Med Genet       Date:  2000-01       Impact factor: 6.318

Review 9.  Open Versus Endovascular or Hybrid Thoracic Aortic Aneurysm Repair.

Authors:  Ryan Clare; Julianne Jorgensen; Somjot S Brar
Journal:  Curr Atheroscler Rep       Date:  2016-10       Impact factor: 5.113

10.  Characterization of the inflammatory cells in ascending thoracic aortic aneurysms in patients with Marfan syndrome, familial thoracic aortic aneurysms, and sporadic aneurysms.

Authors:  Rumin He; Dong-Chuan Guo; Wei Sun; Christina L Papke; Senthil Duraisamy; Anthony L Estrera; Hazim J Safi; Chul Ahn; L Maximilian Buja; Frank C Arnett; Jingwu Zhang; Yong-Jian Geng; Dianna M Milewicz
Journal:  J Thorac Cardiovasc Surg       Date:  2008-06-12       Impact factor: 5.209

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.